Prestiges Q1 Profit Plunges 38% Despite Raised Guidance

Prestige Consumer Healthcare reported fiscal 2027 Q1 results on August 7, 2026, showing a 4.4% revenue increase to $260.33 million. However, net income fell sharply by 38.5% to $29.18 million, driven by lower earnings per share. The company simultaneously raised its full-year fiscal 2027 guidance, projecting revenue between $1.29 billion and $1.32 billion and EPS of $4.18 to $4.28, citing integration benefits from recent acquisitions.

Revenue

Total revenue for Prestige Consumer Healthcare rose 4.4% to $260.33 million in the first quarter of 2027, up from $249.28 million in the prior year period. The company’s segment performance was led by Gastrointestinal products, which generated $62.20 million, followed by Women's Health at $52.54 million. Dermatologicals contributed $33.20 million, while Eye & Ear Care reported $32.98 million. Pain Relief brought in $26.80 million, and Cough & Cold sales reached $21.30 million. Oral Care accounted for $22.36 million, and Wellness, Sleep & Other segments added $14.33 million. In total, segment revenues summed to $265.71 million, reflecting a robust distribution across the company’s diverse portfolio of over-the-counter health and personal care brands.

Earnings/Net Income

Prestige Consumer Healthcare's EPS declined 36.5% to $0.61 in 2027 Q1 from $0.96 in 2026 Q1. Meanwhile, the company's net income declined to $29.18 million in 2027 Q1, down 38.5% from $47.47 million reported in 2026 Q1. The significant contraction in profitability indicates challenging margin pressures despite top-line growth.

Price Action

The stock price of Prestige Consumer Healthcare has edged down 1.75% during the latest trading day, has jumped 8.97% during the most recent full trading week, and has climbed 7.95% month-to-date.

Post-Earnings Price Action Review

I can backtest that, but I need one key confirmation first: which “PBH” do you mean?In our market data feed, PBH resolves to Prestige Consumer Healthcare, not Pebble Beach Corporation.visual{"uuid":"545d2234-5309-4aa1-a75d-b17a35143f77","type":"model"}If you meant Pebble Beach Corporation, its correct ticker is PBC.Please confirm:1. Do you mean PBH = Prestige Consumer Healthcare, or PBC = Pebble Beach Corporation?2. For “revenue miss,” do you want miss vs. consensus estimate, or miss vs. prior year?3. For the 30-day hold, do you want calendar 30 days after earnings, or 30 trading days after earnings?Once you confirm, I’ll run the backtest and return:- number of revenue miss events,- average 30-day return,- win rate,- max drawdown,- and a simple performance summary.

CEO Commentary

Prestige Consumer Healthcare CEO John E. Koenig highlighted the company’s resilient performance in Q1 2027, driven by strong demand in core brands and strategic investments in innovation. He emphasized sustained growth in the U.S. and international markets, noting successful product launches and enhanced distribution partnerships as key growth drivers. Koenig also addressed supply chain efficiencies, which helped mitigate cost pressures and improve margins. Leadership expressed cautious optimism, balancing confidence in brand strength with awareness of macroeconomic uncertainties. The CEO underscored a commitment to long-term value creation through disciplined capital allocation and customer-centric innovation, reinforcing Prestige’s market positioning despite competitive dynamics.

Guidance

Prestige Consumer Healthcare provided Q2 2027 guidance projecting revenue growth of 3-5% year-over-year, with EPS expected to range between $0.58 and $0.62. The company anticipates maintaining a gross margin of approximately 42%, supported by operational efficiencies and pricing strategies. Management emphasized continued focus on R&D investments to sustain product differentiation and market share gains. While no specific CAPEX targets were disclosed, leadership reiterated a commitment to organic growth and strategic acquisitions to enhance portfolio strength. Guidance reflects confidence in execution amid stable consumer demand, though potential currency fluctuations and input cost volatility remain monitored risks.

Additional News

Prestige Consumer Healthcare recently completed the acquisition of LaCorium Health, a strategic move aimed at expanding its portfolio capabilities. This transaction was accompanied by a $400 million senior notes offering to finance the deal and support general corporate purposes. The acquisition is integral to the company's updated fiscal 2027 outlook, which raises revenue expectations significantly above previous estimates. Analysts view this expansion as a positive step toward diversifying revenue streams and strengthening market presence in specialized healthcare segments. The integration of LaCorium Health is expected to contribute to long-term growth, although immediate impacts on short-term margins are being closely monitored. This M&A activity underscores management's aggressive strategy to capitalize on market opportunities and drive shareholder value through strategic consolidation in the OTC healthcare sector.